Loss of the TSC1/TSC2 complex leads to constitutively high mTORC1 signaling; however, pharmacological inhibition of mTORC1 in this setting produces a broad spectrum of clinical responses. We report herein several cell surface proteins upregulated by inactivation of TSC1 that present therapeutic alternatives or adjuvants to direct mTORC1 inhibition. A proteomics screen revealed that TSC1 loss most dramatically induced the expression of neprilysin (NEP/CD10) and aminopeptidase N (APN/CD13). The survival of TSC1 null human cancer cells was dependent on NEP expression, and TSC1 mutation sensitized cells to biochemical inhibition of APN. Remarkably, NEP and APN upregulation occurred via a TSC2-and mTORC1-independent mechanism; therefore, the antiproliferative effects of mTORC1 inhibition could be augmented by co-suppression of APN activity.
Abstract:
Loss of the TSC1/TSC2 complex leads to constitutively high mTORC1 signaling; however, pharmacological inhibition of mTORC1 in this setting produces a broad spectrum of clinical responses. We report herein several cell surface proteins upregulated by inactivation of TSC1 that present therapeutic alternatives or adjuvants to direct mTORC1 inhibition. A proteomics screen revealed that TSC1 loss most dramatically induced the expression of neprilysin (NEP/CD10) and aminopeptidase N (APN/CD13). The survival of TSC1 null human cancer cells was dependent on NEP expression, and TSC1 mutation sensitized cells to biochemical inhibition of APN. Remarkably, NEP and APN upregulation occurred via a TSC2-and mTORC1-independent mechanism; therefore, the antiproliferative effects of mTORC1 inhibition could be augmented by co-suppression of APN activity.
Statement of significance:
These data introduce a non-canonical biological role for TSC1 beyond regulating mTORC1 signaling, which also enabled several immediately translatable therapeutic strategies for clinically problematic cells with TSC1 mutations.
Introduction:
Somatic or germline genetic mutations that inactivate TSC1 or TSC2 contribute to the pathogenesis of several deadly cancers (e.g. bladder, kidney) and debilitating human disorders (e.g. tuberous sclerosis complex, focal cortical dysplasia) 1 . Under normal conditions, TSC1 is known to heterodimerize with TSC2 to provide protection from ubiquitin mediated degradation 2 , while TSC2 employs a GTPase activating protein domain to biochemically convert GTP-Rheb to GDP-Rheb 3 . As GTP-Rheb is required for the activation of mTORC1, loss of the TSC1/TSC2
complex generally results in constitutively high mTORC1 signaling. On this basis, there has been considerable interest in treating clinically problematic cells with inactivating mutations in TSC1 and/or TSC2 by inhibiting mTORC1 signaling 4 .
While TSC1/TSC2 null preclinical models are sensitive to mTORC1 inhibitors [5] [6] [7] , the clinical experience has been comparatively more perplexing. For instance, benign and malignant tubers arising from tuberous sclerosis complex are highly responsive to the rapalogue everolimus (RAD001) [8] [9] [10] . Moreover, somatic TSC1 or TSC2 mutations in bladder, kidney, thyroid, and liver cancers have been associated retrospectively with clinical responses to everolimus, including examples of long term bladder and thyroid cancer remissions [11] [12] [13] [14] [15] . However, not all patients with TSC1 and/or TSC2 mutations experience durable radiographic responses, and it is currently unclear if TSC1 and/or TSC2 mutational status bears any predictive value in treatment naïve patients. These observations could suggest that additional pathobiological events are required to confer sensitivity to mTORC1 inhibition, and/or that loss of TSC1/TSC2 imparts pathobiological effects independent of mTORC1 signaling.
Collectively, these considerations motivated us to apply an unbiased molecular profiling approach to discover alternative therapeutic strategies. Protein signaling on the cell surface is a prominent mechanism of intra-and intercellular communication, and an important component of cellular transformation. Moreover, the accessibility of cell surface proteins enables comparatively more and chemically diverse therapeutic strategies than are available for targeting intracellular proteins, including clinically validated technologies like antibody-drug conjugates and radioimmunotherapy 16 . However, to our knowledge, cell surface protein changes associated with loss of TSC1 or TSC2 had not yet been defined. On this basis, we hypothesized that profiling the cell surface proteome in genetically defined cell line models might identify new therapeutic targets arising from TSC1/TSC2 loss.
Results:
We conducted a LC-MS/MS study to define the cell surface proteome in isogenic pairs of Tsc1 identified was calculated using R and showed strong reproducibility (Supplemental Figure 1A- B). Overall, 20 proteins were predicted to have a median log 2 enrichment ratio
versus Tsc1 +/+ ) with p < 0.05 ( Figure 1A , Supplemental figure 1C, Table 1) . Among these proteins, we were encouraged to see that the transferrin receptor (Tfrc) and glucose transporter 1 (Slc2a1) were overexpressed on the surface of Tsc1 -/-MEFs, consistent with prior literature
showing that mTORC1 upregulates their respective cell surface expression ( Figure 1B ) [19] [20] [21] .
Gene set enrichment analysis (GSEA) of the differentially regulated hits on the cell surface using GO term gene sets identified a significant de-enrichment of genes sets annotated with biological adhesion (Supplemental Figure 2A-D) . Further GSEA using a combination of KEGG, REACTOME, BIOCARTA, and HALLMARK gene sets identified a de-enrichment of the focal adhesion pathway (Supplemental Figure 2E- Figure 2H ). This finding is consistent with previous literature showing that TSC1 regulates cellular adhesion 22 .
Flow cytometry was used to validate the overexpression of the 20 hits predicted to be upregulated in Tsc1 To compare protein expression changes in a human cell line bearing TSC1 knockout, TSC1 was deleted from T24 cell line using CRISPR/Cas9 technology. Two single cell clones (T24 C1, T24 C2) treated with discrete sgRNAs were isolated, expanded and validated for TSC1 knockout ( Figure 1E ). NEP and APN expression levels were significantly higher in the TSC1 knockout sublines compared to parental T24 ( Figure 1E ). NEP and APN biochemical activities were also significantly higher in viable T24 C1 and C2 cells compared to the parental line ( Figure 1F and Supplemental Figure 6A ).
We next tested whether NEP and APN expression and/or activity is required for survival and We next determined if loss of TSC1 sensitizes cells to ablation or inhibition of APN in vitro.
Genetic silencing of Anpep mRNA via siRNA resulted in a statistically larger antiproliferative effect in T24 C1, and T24 C2 compared to parental T24 ( Figure 2D and Supplemental Figure   11 ). Dosing CHR2797 revealed that the IC 50 for growth inhibition in T24 C1 and C2 knockout cells was ~3-6 fold lower than parental T24 ( Figure 2E and Supplemental Figure 12 ). By comparison, T24, T24 C1, and T24 C2 were equally sensitive to doxorubicin, BKM120 (pan p110 inhibitor), and GDC0941 (p110α isoform inhibitor).
CHR2797 was previously shown to suppress mTORC1 signaling, and this struck us as a possible mechanism for the sensitivity of TSC1 null cell lines. 24 However, treating 97-1 cells with CHR2797 had no impact on the phosphorylation levels of mTORC1 substrates in our hands ( Figure 3A) . Moreover, treatment of TSC1 null cell lines with RAD001, BEZ235, or INK128
did not reduce APN expression, suggesting that the induction of APN by loss of TSC1 is mTORC1 independent ( Figure 3B and Supplemental Figure 13A and 13B). Consistent with this model, APN expression levels were also not upregulated in Tsc2 -/-versus Tsc2 +/+ MEFs (nor was APN expression detectable in Tsc2 +/+ , see Figure 3C and Supplemental Figure 14) .
The observation that induction of APN by loss of TSC1 in a mTORC1 independent manner led us to propose that combined APN and mTORC1 inhibition may result in greater antiproliferative effects in TSC1 mutant cells. To this end, we treated TSC1 null cancer cell lines with CHR2797 alone and in combination with BKM120, GDC0941, BYL719 (p110α isoform inhibitor), or
MKK2206 (pan Akt inhibitor). Proliferation of all cell lines was sensitive to kinase inhibition
with single agents at 3 or 5 days post treatment but proliferation was significantly slower when co-treat with CHR2797 ( Figure 3D and Supplemental Figure 15 ). This suggest that while APN and mTORC1 are both induced through the loss of TSC1, they act through independent mechanism in driving proliferation.
Discussion:
The overall goal of this manuscript was to develop new strategies to treat clinically problematic cells arising from the loss of the prominent tumor suppressor complex TSC1/TSC2. An unbiased proteomics screen in Tsc1 -/-and Tsc1 +/+ MEFs identified 12 candidate cell surface antigens, five of which were strongly induced by TSC1 loss. Deeper study of the two most upregulated antigens, NEP and APN, suggest they may be potential drug targets, as silencing either protease potently inhibited the proliferation of TSC1 mutant human cancer cells, while treatment with the human ready APN inhibitor CHR2797 suppressed proliferation in vitro and in vivo. While human TSC1 knockout cells appeared to be more sensitive to genetic and biochemical suppression of APN compared to an isogenic parental cell line, we were also struck by the observation that neither NEP nor APN expression was dependent on TSC2 or mTORC1.
This observation led to the non-obvious insight that the bioactivity of APN inhibition can be augmented combined suppression of mTORC1 signaling.
To our knowledge, no prior association has been established between TSC1 loss, and NEP or APN overexpression, though NEP and APN expression has been observed in human cancers with frequent TSC1 mutation [25] [26] [27] [28] [29] proportionate to those used for our animal studies. We are also hopeful that our data will motivate interest in combining CHR2797 with any of the available clinically active PI3K pathway inhibitors, perhaps in setting like metastatic bladder cancer, given the frequency of TSC1 mutation and the standing interest in treating this malignancy with mTORC1 inhibitors.
Although NEP and APN emerged as obvious targets for immediate study, some of the other hits
emerging from the proteomics screen may have utility. For instance, TFRC is a well-established target for molecular imaging [34] [35] [36] , and radiolabeled transferrin molecules may be useful for detecting cells with TSC1 mutations. To our knowledge, GSGL1 and AGRL2 are essentially unstudied as drug or diagnostic targets. The G-coupled protein receptor AGRL2 in particular may emerge as an interesting new target, owing to its limited expression in normal tissues. More generally, our success in identifying new drug targets for TSC1 and RAS driven cancers using cell surface proteomics argues strongly that this approach may scale well to other common oncogenic drivers 37 .
Materials and Methods:
General methods: Cells were mixed at a 1:1 cell count ratio prior to cell surface capture enrichment. Briefly, live cells were treated with a sodium periodate buffer (2 mM NaIO 4 , PBS pH 6.5) at 4°C for 20 mins to oxidize terminal sialic acids of glycoproteins. Aldehydes generated by periodate oxidation were then reacted with biocytin hydrazide in a labeling buffer (1 mM biocytin hydrazide (biotium), 10 mM analine (Sigma), PBS pH 6.5) at 4°C for 90 mins. Cells were then washed four times in PBS pH 6.5 to remove excess biocytin-hydrazide and flash frozen.
Frozen cell pellets were lysed using RIPA buffer (VWR) with protease inhibitor cocktail (SigmaAldrich; St. Louis, MO) at 4°C for 30 mins. Cell lysate was then sonicated, clarified, and incubated with 500µL of neutravidin agarose slurry (Thermo Fisher Scientific) at 4°C for 30
mins. The neutravidin beads were then extensively washed with RIPA buffer, high salt buffer (1M NaCl, PBS pH 7.5), and urea buffer (2M urea, 50mM ammonium bicarbonate) to remove non-specific proteins. Samples were then reduced on-bead with 5mM TCEP at 55°C for 30 mins and alkylated with 10mM iodoacetamide at room temperature for 30 mins. To release bound proteins, we first performed an on-bead digestion using 20µg trypsin (Promega; Madison, WI) at room temperature overnight to remove any non-specific protein binders. The neutravidin beads were extensively washed again with RIPA buffer, high salt buffer (1M NaCl, PBS pH 7.5), and urea buffer (2M urea, 50mM ammonium bicarbonate). To release trypsin digested Nglycosylated peptides bound to the neutravidin beads, peptides were released using 2500U
PNGase F (New England Biolabs; Ipswich, MA) at 37°C for 3 hours and eluted using a spin column. PNGase F released peptides were then desalted using SOLA HRP SPE column (Thermo Fisher Scientific) using standard protocol, dried, and dissolved in 0.1% formic acid, 2%
acetonitrile prior to LC-MS/MS analysis. Immunoblot: Cell pellets were lysed in RIPA buffer with protease and phosphatase inhibitor cocktails (Calbiochem) and then resolved using 1D SDS PAGE. Protein concentration was determined with a Bradford absorbance assay, and equal amounts of protein (10-30 μg of lysate)
Mass spectrometry analysis:
were separated by SDS-PAGE, transferred to PVDF membranes, and immunoblotted with specific primary and secondary antibodies. Immunoreactive bands were visualized using enhanced chemiluminescence (ECL) and detected by chemiluminescence with the ECL detection reagents from Thermo Scientific.
Real time PCR:
Cellular RNA was harvested with a RNAeasy mini kit (Qiagen) using a
Qiashredder to disrupt cell pellets. The purity and concentration of RNA was quantified using a NanoDrop spectrometer (ThermoScientific), and 1.5 μg of RNA was converted to cDNA with a high capacity cDNA reverse transcription kit (Applied Biosystems). Relative changes in mRNA levels were assessed with a Pikoreal rtPCR cycler (Thermo Fisher Scientific). ΔCt was calculated using the respective actin control, and ΔΔCt was calculated by normalizing ΔCt values to that of vehicle control. Data were expressed as 2 siRNA solutions were prepared Opti-MEM medium. After adding siRNA, the final concentration of siRNA was 40 nM in each well. 72 h after transfection, cells were counted by CellTiter-Glo.
mRNA silencing was confirmed in separate wells using rtPCR.
Apoptosis assay: Apoptosis of cells was detected by using the Caspase-Glo 9 assay (Promega).
For detection of caspase activity and apoptosis, cells (2 x 10 
